Diabetic nephropathy, a severe microvascular complication of diabetes mellitus, is the most common form of chronic kidney disease and a leading cause of renal failure in end-stage renal disease. No currently available treatment can achieve complete cure. Palatin Announced Today Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy · Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy · Demonstrated efficacy at 6 months o 71% percent of patients achieved a >30% reduction in the urine protein to creatinine ratio (UP/Cr) o 71% of patients achieved improved or stabilized estimated glomerular filtration rate (eGFR) · Bremelanotide therapy increased urinary VEGF levels in 37.5% of patients and reduced urinary synaptopodin losses in 36% of patients The data from this trial is encouraging and validates that modulating the melanocortin system could potentially be a new therapeutic strategy and possibly disease-modifying treatment option for people living with this progressive kidney disease.
Healthtech Exec Committed to Patient-First Innovation | Ro Employee #3 | Startup Leader | Strategic Advisor | Builder of High-Performing Teams
2dThis is interesting. I am interested to see how much it adds when patients are on the full suite of therapies for this indication, including an SGLT2 inhibitor and finerenone.